Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients
Open Access
- 4 September 2014
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 178 (1), 40-47
- https://doi.org/10.1111/cei.12390
Abstract
Summary: Rituximab (RTX) treatment in rheumatoid arthritis (RA) patients severely hampers humoral response after influenza vaccination as determined by haemagglutination inhibition assay (HI). It is not known whether HI reflects both immunoglobulin (Ig)M and IgG (subclass) influenza response, and whether IgM antibodies contribute to the low rate of influenza infection seen in RA patients. Twenty RA patients on methotrexate (MTX), 23 on RTX and 28 healthy controls (HC) received trivalent influenza subunit vaccination. Before and 28 days after vaccination, H1N1- and H3N2-specific antibodies were measured by HI and by IgM and IgG (subclass) enzyme-linked immunosorbent assay (ELISA). B cell activating factor (BAFF) levels were determined in serum samples before vaccination. Vaccination induced a significant increase of IgM and IgG (IgG1 and IgG3) antibodies against both strains in the HC and MTX groups (all P < 0·01), but not in the RTX group. HI correlated significantly in all cases with IgG (IgG1) but not with IgM. In RTX late patients (RTX treatment 6–10 months before vaccination), IgG (IgG1 and IgG3) response to vaccination was restored, but not IgM response. BAFF levels were significantly increased in RA-RTX patients and correlated with total IgG levels. Haemagglutination inhibition assay, used as gold standard, detects primarily IgG (IgG1) responses. IgM- and IgG influenza-specific antibodies increase after vaccination in HC and RA patients except in patients on RTX treatment. BAFF levels are increased in both early and late RTX-treated patients, but do not correlate with an influenza-specific antibody response.Keywords
Funding Information
- Roche Nederland and Solvay Pharmaceuticals
This publication has 31 references indexed in Scilit:
- Development of an enzyme‐linked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusionInfluenza and Other Respiratory Viruses, 2012
- Effect of rituximab on human in vivo antibody immune responsesJournal of Allergy and Clinical Immunology, 2011
- TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid ArthritisMedicine, 2011
- The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximabVaccine, 2011
- The immortality of humoral immunityImmunological Reviews, 2010
- Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatmentArthritis Research & Therapy, 2010
- Initiation of rheumatoid arthritis treatments and the risk of serious infectionsRheumatology, 2009
- Infections and treatment of patients with rheumatic diseases.2008
- Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapseArthritis & Rheumatism, 2006
- The Effect of Age and Natural Priming on the IgG and IgA Subclass Responses after Parenteral Influenza VaccinationThe Journal of Infectious Diseases, 1999